Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Eduard Schmulenson, Nigina Zimmermann, Gerd Mikus, Markus Joerger & Ulrich Jaehde. (2021) Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opinion on Drug Metabolism & Toxicology 17:12, pages 1407-1422.
Read now
Read now
Lonneke Timmers, Eleonora L Swart, Christel CLM Boons, Dirk Mangnus, Peter M van de Ven, Godefridus J Peters, Epie Boven & Jacqueline G Hugtenburg. (2012) The use of capecitabine in daily practice: a study on adherence and patients’ experiences. Patient Preference and Adherence 6, pages 741-748.
Read now
Read now
A.B. P. van Kuilenburg, J.G. Maring, A. Schalhorn, C. Terborg, H. Schmalenberg, D. Behnke, W. Schwabe, K. Jabschinsky & P. Hausler. (2008) Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene. Nucleosides, Nucleotides & Nucleic Acids 27:6-7, pages 692-698.
Read now
Read now
Articles from other publishers (7)
Markus Joerger, Christoph Ritter & Susen Burock. 2020. Kompendium Internistische Onkologie. Kompendium Internistische Onkologie
1
8
.
Seema Kohli & Lavakesh Kumar Omray. 2022. Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology. Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology
165
179
.
Bushra Salman & Murtadha Al-Khabori. (2020) Applications and challenges in therapeutic drug monitoring of cancer treatment: A review. Journal of Oncology Pharmacy Practice 27:3, pages 693-701.
Crossref
Crossref
André BP van KuilenburgJan Gerard Maring. (2013) Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics 14:7, pages 799-811.
Crossref
Crossref
André B. P. van Kuilenburg, Peter Häusler, Andreas Schalhorn, Michael W. T. Tanck, Johannes H. Proost, Christoph Terborg, Detlev Behnke, Wolfgang Schwabe, Kati Jabschinsky & Jan Gerard Maring. (2012) Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy. Clinical Pharmacokinetics 51:3, pages 163-174.
Crossref
Crossref
M Gusella, A C Frigo, C Bolzonella, R Marinelli, C Barile, A Bononi, G Crepaldi, D Menon, L Stievano, S Toso, F Pasini, E Ferrazzi & R Padrini. (2009) Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. British Journal of Cancer 100:10, pages 1549-1557.
Crossref
Crossref
M. Gusella, G. Crepaldi, C. Barile, A. Bononi, D. Menon, S. Toso, D. Scapoli, L. Stievano, E. Ferrazzi, F. Grigoletto, M. Ferrari & R. Padrini. (2006) Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Annals of Oncology 17:11, pages 1656-1660.
Crossref
Crossref